These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27039292)

  • 21. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
    Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
    Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression.
    Guo L; Zheng J; Zhang J; Wang H; Shao G; Teng L
    Oncol Rep; 2016 Aug; 36(2):729-36. PubMed ID: 27373987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
    Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
    J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
    Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
    EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crosstalk between Hippo and TGFβ: Subcellular Localization of YAP/TAZ/Smad Complexes.
    Grannas K; Arngården L; Lönn P; Mazurkiewicz M; Blokzijl A; Zieba A; Söderberg O
    J Mol Biol; 2015 Oct; 427(21):3407-15. PubMed ID: 25937570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways.
    Zhao Y; Montminy T; Azad T; Lightbody E; Hao Y; SenGupta S; Asselin E; Nicol C; Yang X
    Mol Cancer Res; 2018 Jun; 16(6):1046-1058. PubMed ID: 29545474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis.
    Gill MK; Christova T; Zhang YY; Gregorieff A; Zhang L; Narimatsu M; Song S; Xiong S; Couzens AL; Tong J; Krieger JR; Moran MF; Zlotta AR; van der Kwast TH; Gingras AC; Sicheri F; Wrana JL; Attisano L
    Nat Commun; 2018 Aug; 9(1):3510. PubMed ID: 30158528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aurora A kinase activates YAP signaling in triple-negative breast cancer.
    Chang SS; Yamaguchi H; Xia W; Lim SO; Khotskaya Y; Wu Y; Chang WC; Liu Q; Hung MC
    Oncogene; 2017 Mar; 36(9):1265-1275. PubMed ID: 27593935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis.
    Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY
    Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 37. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
    Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
    Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
    J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
    Zhang L; Wang XI; Zhang S
    Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
    Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
    Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.